EQS-News: MeVis publishes figures for the first half of fiscal year 2023/2024
|
EQS-News: MeVis Medical Solutions AG
/ Key word(s): Half Year Results
Bremen, May 27, 2024 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company, today announced its results for the first half of fiscal year 2023/2024, reporting period October 1, 2023 to March 31, 2024. In the first half of the year, the company's revenue amounted to € 8,774 k (previous year: € 8,472 k). Of this figure, 27 % (previous year: 26 %) is attributable to the sale of licenses, 35 % (previous year: 35 %) to maintenance revenue and 38 % (previous year: 39 %) to other revenue, which includes services for and recharges to affiliated companies and the parent company. Earnings before interest and taxes (EBIT) rose from € 1,893 k to € 2,735 k, which corresponds to an EBIT margin of 24 %, mainly due to the lower expenses from currency translation compared to the previous year. Income from loans of financial assets amounted to € 643 k (previous year: € 624 k) and is attributable to interest income from the loan granted to Varex Imaging Deutschland AG. This results in earnings before taxes (EBT) of € 2,735 k (previous year: € 1,893 k). Income taxes of € 74 k (previous year: € 64 k) were incurred in the past half year, therefore, taking into account the expenses from the profit to be transferred to Varex Imaging Deutschland AG in the amount of € 2,661 k (previous year: € 1,829 k), net income for the year amounted to € 0 k (previous year: € 0 k). At this point in time, we are sticking to our forecast: for the 2023/2024 financial year, sales are now expected to increase slightly year-on-year to between € 18.0 m and € 18.5 m. In addition to the slight increase in sales with the customer Hologic, sales in the lung and liver area are also expected to increase slightly. We expect a slight decline in the area of development services. For earnings before interest and taxes (EBIT), we expect stability in the range of € 4.5 m to € 5.0 m. The forecast slight growth in sales and the simultaneous increase in personnel costs and other operating expenses are key drivers for the EBIT outlook. As in the past reporting period, the Executive Board will regularly review its expectations in the course of fiscal 2022/2023 on the basis of current business performance. Contact: Kirchhoff, Marcus / CEO
27.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | MeVis Medical Solutions AG |
| Caroline-Herschel-Str. 1 | |
| 28359 Bremen | |
| Germany | |
| Phone: | +49 421 224 95 0 |
| Fax: | +49 421 224 95 999 |
| E-mail: | ir@mevis.de |
| Internet: | http://www.mevis.de |
| ISIN: | DE000A0LBFE4 |
| WKN: | A0LBFE |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1911777 |
| End of News | EQS News Service |
|
|
1911777 27.05.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 16,76 | 18,07 | 17,13 | 16,21 | 18,76 | 17,34 | 18,30 | |
| EBITDA1,2 | 7,60 | 8,25 | 5,97 | 4,77 | 7,99 | 3,99 | 4,91 | |
| EBITDA-Margin3 | 45,35 | 45,66 | 34,85 | 29,43 | 42,59 | 23,01 | 26,83 | |
| EBIT1,4 | 6,69 | 8,00 | 5,81 | 4,64 | 7,90 | 3,89 | 4,80 | |
| EBIT-Margin5 | 39,92 | 44,27 | 33,92 | 28,62 | 42,11 | 22,43 | 26,23 | |
| Net Profit (Loss)1 | 7,17 | 8,07 | 5,70 | 4,55 | 7,79 | 4,92 | 5,70 | |
| Net-Margin6 | 42,78 | 44,66 | 33,28 | 28,07 | 41,53 | 28,37 | 31,15 | |
| Cashflow1,7 | 5,52 | 6,55 | 2,89 | 9,13 | 4,86 | 5,85 | 0,00 | |
| Earnings per share8 | 3,94 | 4,43 | 3,13 | 2,50 | 4,28 | 2,70 | 3,15 | |
| Dividend per share8 | 0,95 | 0,95 | 0,95 | 0,95 | 0,95 | 0,95 | 0,95 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Deloitte
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| MeVis Med. Solutions | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0LBFE | DE000A0LBFE4 | AG | 44,41 Mio € | 16.11.2007 | Halten | 9F5C4V35+HX |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 10,17 | 10,24 | 0,99 | 7,43 | 2,49 | 7,59 | 2,56 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,95 | 0,95 | 0,95 | 3,89% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 19.03.2024 | - | 27.05.2025 | - | 30.01.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +0,25% | -2,36% | -3,17% | -3,17% | -55,64% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
